News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an AI-driven analysis of Oxford Lane Capital Corp. Preferred Stock Shares (OXLCO), indicating a neutral sentiment with support being tested. It outlines specific institutional trading strategies for various risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis …
Deep Track Capital and its affiliates have reported a beneficial ownership of 8.33% in X4 Pharmaceuticals (XFOR), totaling 8,040,894 shares with shared voting and dispositive power. This stake includes 2,162,137 Pre-Funded Warrants, which are subject to a 9.99% "Maximum Percentage" ownership cap, limiting their …
This article reports on an SEC Form 144 filing by X4 Pharmaceuticals, Inc. (XFOR) on August 13, 2026. The filing indicates a proposed sale of 24,576 shares of common stock with an aggregate market value of $111,943.68, acquired through restricted stock unit vesting. The …
John Volpone, President of X4 Pharmaceuticals (NASDAQ: XFOR), sold 24,576 shares of company stock on August 12, 2026. This transaction was executed to cover personal income tax liabilities associated with the settlement of a restricted stock unit (RSU) award. Following the sale, Volpone beneficially …
John Volpone, President of X4 Pharmaceuticals (NASDAQ:XFOR), sold 24,576 shares of the company's stock for a total of $109,117.44, reducing his holdings by 8.48%. The sale occurred on August 12th, with the stock trading at an average price of $4.44. X4 Pharmaceuticals recently reported …
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of the company's stock for a total of $210,615.84, reducing his direct stake by 12.61%. This transaction follows the company's recent earnings report where it surpassed analyst expectations for both revenue and adjusted EPS. Despite …
X4 Pharmaceuticals' Executive Chairman, Craig R., sold 47,436 shares of the company's common stock for $210,829 to cover personal income tax obligations related to a restricted stock unit award. Despite this sale, analysts remain bullish on X4 Pharma, with Wells Fargo and Leerink initiating …
X4 Pharmaceuticals (NASDAQ:XFOR) recently reported strong quarterly results, with revenue significantly exceeding expectations and a smaller-than-predicted loss per share. Following these results, analysts have substantially increased their revenue forecasts and reduced estimated losses for 2026, also boosting their price targets for the company. Despite …
Analysts have significantly upgraded their revenue forecasts for X4 Pharmaceuticals, Inc. for 2026, now expecting US$16 million, up from US$9.6 million, and have also reduced loss estimates to US$0.67 per share. Despite the positive adjustments, the company's projected revenue growth rate of 1.7% until …
This article provides an earnings forecast for Oxford Industries Inc (OXM), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 6 analysts, the stock has a "Hold" rating with an average price target of $48.50. The expected revenue for …
This article provides an AI-driven analysis of Oxford Industries Inc. (NYSE: OXM), highlighting a neutral sentiment in the near term that could mitigate mid-term weakness. It details specific institutional trading strategies (Long, Momentum Breakout, Short) with entry, target, and stop-loss zones, alongside multi-timeframe signal …
Guggenheim has reiterated its Buy rating for X4 Pharmaceuticals (XFOR.US) and maintained its price target of $12. This indicates a continued positive outlook from the firm regarding the company's stock performance.
This article provides a comprehensive stock analysis of Oxford Industries Inc (OXM) by TradingKey. It highlights the company's stable fundamentals, high growth potential, and fair valuation within the Textiles & Apparel industry, despite a recent market downturn. Key insights include high institutional ownership, analyst …
X4 Pharmaceuticals (NASDAQ:XFOR) reported its quarterly earnings, posting a loss of $0.13 per share, which beat analyst estimates by $0.05. Despite an unprofitable financial standing with significant negative margins, the stock saw a slight increase of 0.5% to $4.17. Analysts generally maintain a "Moderate …
X4 Pharmaceuticals reported its second-quarter 2026 financial results, highlighting strengthened clinical operations for its 4WARD Phase 3 chronic neutropenia trial and the European Commission's approval of XOLREMDI® (Mavorixafor) for WHIM Syndrome. The company also announced a cash runway extending into 2029. Key accomplishments include …
This article from TradingKey provides current stock information for Oxford Industries Inc (OXM), including its real-time price, market capitalization, and a brief overview of its performance. It notes that more news regarding OXM's earnings, analyst ratings, and key developments will be available soon. The …
Search by ticker symbol or company name and select a result to open its chart.